Nitazoxanide Therapy for Patients With COVID-19 Pneumonia
Status:
Completed
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
Multicenter, randomized, placebo-controlled, parallel, blinded, interventional, treatment
clinical trial with two arms.
Population: 500 Hospitalized patients with pneumonia derived from COVID-19 (Coronavirus
Disease-19), either confirmed by RT-PCR (Real Time polymerase chain reaction), or suggested
by typical findings on the computed tomography scan symptomatic.
Experimental group: nitazoxanide 500mg 8 / 8 hours for 5 days. Control group: placebo 8/8
hours for 5 days.
Phase:
Phase 2
Details
Lead Sponsor:
Universidade Federal do Rio de Janeiro
Collaborators:
ATCGen Complexo Hospitalar do Trabalhador de Curitiba Complexo Hospitalar Municipal de São Caetano do Sul Financiadora de Estudos e Projetos Hospital Central da Aeronáutica, Rio de Janeiro Hospital da Força Aérea do Galeão Hospital das Clínicas da Universidade Federal de Pernambuco Hospital das Clínicas Luzia de Pinho Melo Hospital das Forças Armadas, Brazil Hospital de Força Aérea de São Paulo Hospital Eduardo de Menezes Hospital Estadual de Doenças Tropicais Dr Anuar Auad Hospital Geral de Fortaleza Hospital Geral de São Mateus Dr Manoel Bifulco Hospital Municipal de Barueri Dr Francisco Moran Hospital Naval Marcilio Dias Hospital Regional da Asa Norte, Brazil Hospital Regional de Sorocaba Dr Adib Domingos Jatene Hospital Universitario Pedro Ernesto Mater Dei Hospital, Brazil Ministry of Science and Technology, Brazil National Research Council, Brazil Santa Casa de Misericórdia de Belo Horizonte